Join the Farxiga group to help and get support from people like you.
Farxiga News
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 – Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study published online March...
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
MONDAY, Feb. 24, 2025 – For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared...
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 – For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1...
Diabetes Remission Increased With Dapagliflozin Plus Calorie Restriction
MONDAY, Jan. 27, 2025 – For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated with a significantly higher rate of remission of...
Certain Meds and Diet Can Reverse Type 2 Diabetes
FRIDAY, Jan. 24, 2025 – People can reverse their type 2 diabetes through a combination of calorie cutting and medication, a small clinical trial says. Overweight and obese adults caused their...
AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF >40 Percent
TUESDAY, Nov. 26, 2024 – From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death
MONDAY, Nov. 11, 2024 – The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says. GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes m...
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
THURSDAY, Sept. 19, 2024 – A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inh...
Metformin, SGLT2 Inhibitors Exhibit Significantly Lower Dementia Risk
MONDAY, July 15, 2024 – Compared with other antidiabetic classes, metformin and sodium glucose co-transporter-2 inhibitors (SGLT2is) exhibit significantly lower dementia risk, according to a review...
FDA Approves Farxiga (dapagliflozin) for Glycemic Control in Children Aged 10 Years and Older with Type-2 Diabetes
12 June 2024 – AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged ...
Early Dapagliflozin Does Not Impact Diuretic Efficiency in Acute Heart Failure
THURSDAY, May 9, 2024 – For patients with acute heart failure (AHF), early initiation of dapagliflozin does not affect diuretic efficiency, according to a study published in the April 9 issue of the...
Farxiga Extended in the US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to a Broader Range of Patients
May 9, 2023 – AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) ...
Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
30 April 2021 Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction...
Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 – AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (...
Further information
Related condition support groups
Heart Failure, Congestive Heart Failure, Chronic Kidney Disease, Diabetes, Type 2